Full-Time

Scientist I

Analytical Development for Characterization

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$125k - $133kAnnually

+ Equity Component + Comprehensive Benefits

Mid, Senior

San Carlos, CA, USA

Position is onsite in San Carlos, CA.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • B.S. in Chemistry, Analytical Chemistry preferred, Organic / Biochemistry considered, with 8+ years of relevant industry experience, M.S. with 5+ years, or Ph.D. with 2+ years relevant industry experience.
  • Ideal candidate will have a background in analytical chemistry principles and hands-on experience with modern analytical instrumentations commonly used in the analysis and characterization of drug candidates. Candidates with other scientific disciplines may be considered based on relevant experience.
  • Experience in chemical and biological assays such as colorimetric/fluorimetric microplate assays and HPLC.
  • Experience working with protein analysis – UV-Vis, CE, BCAs etc.
  • Experience working with carbohydrate analysis and SEC-MALS a plus.
  • Understanding of basic principles of analytical method development/ validation/ qualification concepts.
  • Attention to detail and excellent skills in record keeping / documentation. Critical thinking and ability to analyze data.
  • Strong interpersonal skills; ability to communicate effectively both verbally and in written formats.
  • Ability to work under supervision and independently in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.
Responsibilities
  • Assist in the design, execution and interpretation of experiments to analyze drug substances and intermediates such as proteins and carbohydrates including:
  • Microplate assays including enzymatic assays
  • HPLC- Especially SEC and RP-HPLC with experience in Chemstation
  • CE and iCIEF – Especially with Protein Simple or PA-800 systems
  • SEC-MALS for a variety of molecules.
  • Assist in analytical method development of new assays.
  • Keep accurate and detailed records of experiments.
  • Summarize data and communicate to analytical team.
  • Support daily lab operations, sample inventory and sample shipment.
  • Work within a team environment and provide support to further team objectives.
  • Complete any assigned tasks in high quality and in a timely manner.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options